Zivo Bioscience, Inc. Executes Letters of Intent with India-Based Algae Producers, Ships Algal Starter Inoculum to Growers in Taiwan

KEEGO HARBOR, MI / ACCESSWIRE / April 24, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that Wellisen Nutraceuticals and Sanat Products Ltd., both established algae producers located in the Indian subcontinent's southernmost region, have executed letters of intent to produce the ZIVO algae strain exclusively for ZIVO under a license from ZIVO. The Company is in the process of transferring its proprietary strain to laboratories in India. Simultaneously, ZIVO is shipping living algae inoculum to Taiwan for production scaleup on the island nation's southeast coastline, where algae production has been commonplace for decades. The Company is providing incentives and licensing opportunities to convert ponds from spirulina to ZIVO strain production.

"It's the fastest, most capital-efficient approach to rapidly scale up production, and keep that production volume consistent," states Andrew A. Dahl, President & CEO. "We're working with established growers who have decades of experience growing other forms of algae at commercial scale, so we can work toward getting economies of scale in a relatively short timeframe."

The Company is producing its starter inoculum in the United States, and then shipping the living algae to laboratories and production facilities in Asia and India. At the same time, the Company has filed applications for patents in Taiwan, India and mainland China.

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

Contact:

Investor Relations
(248) 452 9866 ext. 150
ZIVO Bioscience, Inc.
[email protected]

SOURCE: ZIVO Bioscience, Inc.